Mark Johnson | VP, IR |
Steve Davis | CEO |
Elena Ridloff | CFO |
Amanda Morgan | Chief Revenue and Customer Officer |
Charmaine Lykins | Global Product Planning and Chief Marketing Officer |
Serge Stankovic | President |
Cory Kasimov | JPMorgan |
Ritu Baral | Cowen & Company |
Tazeen Ahmad | Bank of America |
Charles Duncan | Cantor Fitzgerald |
Neena Bitritto-Garg | Citi |
Jason Butler | JMP Securities |
Jeff Hung | Morgan Stanley |
Salveen Richter | Goldman Sachs |
Marc Goodman | SVB Leerink |
Vamil Divan | Mizuho Securities |
Paul Matteis | Stifel Nicolaus |
Gregory Renza | RBC Capital Markets |
Sumant Kulkarni | Canaccord Genuity |
Chris Howerton | Jefferies |
Joseph Stringer | Needham & Company |
Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals' Fourth Quarter and Full-Year 2020 Financial Results Conference Call. My name is Giji, and I will be your coordinator for today. At this time, all participants are in listen-only mode.
We will be facilitating a question-and-answer session toward the end of today's call. [Operator Instructions] I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA.